News

Wednesday, 13. March 2024 | Filed under Company News

MetrioPharm Establishes Scientific Advisory Board of Seasoned Immunology and Pediatric Experts

— The new advisors will supply expertise in immunology, pathology, inflammatory processes and in MetrioPharm’s lead indication Duchenne muscular dystrophy

— Advisors have previously collaborated with MetrioPharm on strategic and scientific projects

— Advisors bring expertise to further advance MetrioPharm´s pipeline

MetrioPharm AG, a clinical stage biotech company developing drugs for inflammatory and infectious diseases, today announced that it has established a Scientific Advisory Board (SAB). Read more…

Tuesday, 5. March 2024 | Filed under Company News

BellaSeno’s 3D-printed Resorbable Scaffold Successfully Used in Critical-Size Large Segmental Radius Bone Defect at Hannover Medical School

— Trauma patient suffered from third degree open infected fracture of its radial shaft after injury by a bullet

— Graft vascularization was achieved by embedding vascular pedicle into the scaffold

— Recently published as a case report in the Journal of Personalized Medicine

BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, announced today that a team at the Hannover Medical School, Clinic for Trauma Surgery, led by Prof. Dr. med. Philipp Mommsen, successfully used a customized, resorbable bone replacement scaffold produced by BellaSeno to reconstruct a 14 cm segmental bone defect of the radial shaft after third degree open infected fracture due to traumatic gunshot injury.

Read more…

Tuesday, 20. February 2024 | Filed under Company News

Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6

– Designation underlines the need for novel, first-in-class antimicrobials for the treatment of infections with Gram-negative bacteria

Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced that the Company has received fast-track designation for its novel anti-infective OMN6 from the U.S. Food and Drug Administration (FDA). Fast track expedited review is designated to investigational drugs that treat a serious or life-threatening condition and fill an unmet medical need.

Read more…